NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
He holds a Bachelor’s Degree in Science and has joined the company in 2012 and has over 10 years of experience in pharmaceutical industry
The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017
Subscribe To Our Newsletter & Stay Updated
